Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Likely To Play Up Saphris' Safety In Q4 Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.

You may also be interested in...



Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

Company will use newly acquired Sepracor sales force for the atypical antipsychotic.

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

Company will use newly acquired Sepracor sales force for the atypical antipsychotic.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel